Sanofi will acquire the London-based vaccine startup Vicebio for $1.15 billion upfront and as much as $450 million in future payments, the companies said Tuesday. The deal marks Sanofi’s fourth acquisition of the year, following the recently completed $9 billion purchase of commercial-stage drugmaker Blueprint Medicines, an Alzheimer’s pipeline expansion with a $470 million deal…
Read article
In 2020, Jaci Hermstad died at age 26 from a rare and aggressive form of ALS. But her story didn’t end there. A drug that was created just for her, called Jacifusen, has since been given to others with mutations in the FUS gene, what’s known as FUS-ALS. The results in the first 12 patients, published…
Read article
At long last, Anne Wojcicki has officially bought 23andMe. The co-founder and former CEO’s nonprofit, TTAM Research Institute, on Monday said it had completed the acquisition of 23andMe’s consumer genetics business and its research unit. In June, Wojcicki’s TTAM won a bid to acquire 23andMe for $305 million as part of bankruptcy proceedings. Regeneron had…
Read article